Tetraphase Pharmaceuticals doses its first patient in Phase III trials of Eravacycline

Tetraphase Pharmaceuticals (TTPH +3.4%) gains after saying it's first patient was dosed in Phase III testing of its Eravacycline drug candidate for the treatment of complicated intra-abdominal infections.

The company is also planning for a late-stage trial using the drug in complicated urinary tract infections.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs